Citations

Clear

6 citation(s) found for "Kim, Minchul".

Gender differences in patient experience in idiopathic inflammatory myopathies: Subanalysis from the COVAD dataset
Yoshida, Akira , Kim, Minchul , Kuwana, Masataka , Ravichandran, Naveen, Kardeş, Sinan , Milchert, Marcin , Salim, Babur , Velikova, Tsvetelina , Parodis, Ioannis , Nikiphorou, Elena , Tan, Ai Lyn , Ziadé, Nelly , Chinoy, Hector , Agarwal, Vikas , Gupta, Latika, Singh, Yogesh Preet , Pauling, John D , Wincup, Chris , Parisi, Simone , Sainaghi, Pier Paolo , Angelis, Rossella De , Loarce‐Martos, Jesus , Gupta, Latika , Gupta, Latika , Milchert, Marcin , Agarwal, Vikas , Velikova, Tsvetelina , Parodis, Ioannis , Tan, Ai Lyn , Ziade, Nelly , Chinoy, Hector , Pauling, John D , Wincup, Chris , Yoshida, Akira , De Angelis, Rossella , Singh, Yogesh Preet , Ravichandran, Naveen, Makol, Ashima , Sen, Parikshit , Lilleker, James B , Agarwal, Vishwesh , Day, Jessica , Joshi, Mrudula , Gheita, Tamer A. , Gracia‐Ramos, Abraham Edgar , Chatterjee, Tulika , Nune, Arvind , Cavagna, Lorenzo , Saavedra, Miguel A , Shinjo, Samuel Katsuyuki , Knitza, Johannes , Distler, Oliver , Aggarwal, Rohit

Mayo Clinic

Modern Rheumatology | September 28, 2023 | Volume: 34 | Issue: 4 | Pages: 756-766

10.1093/mr/road094 | PMID 37769200 Get It

ABSTRACTObjectivesWe aimed to investigate the gender-based differences in idiopathic inflammatory myopathies (IIMs), with a particular focus on patient-reported outcomes, utilizing the data obtained through the international COVID-19 vaccination in autoimmune disease e-survey.MethodsPatient-reported outcomes including fatigue, pain, and physical function were extracted from the COVID-19 vaccination in autoimmune disease database and compared between genders, adjusting for demographics and IIM subgroups by multivariable analysis. Inclusion body myositis (IBM) was analysed separately because of the substantial differences in outcomes.ResultsA total of 1197 complete responses from patients with IIMs as of 31 August 2021 were analysed. Seventy percent were women. Women were younger (58 [48–68] vs. 69 [58–75] years old, median [interquartile range], P < .001) and were more likely to suffer from autoimmune multimorbidity, defined as three or more autoimmune diseases in an individual patient (11.4% vs. 2.8%, P < .001). In non-IBM IIMs, fatigue visual analogue scale scores were higher in women (5 [3–7] vs. 4 [2–6], median [interquartile range], P = .004), whereas no significant gender-based differences were noted in IBM. Multivariable analysis in non-IBM IIMs revealed that women, residence in high-income countries, overlap myositis, and autoimmune multimorbidity were independently associated with increased fatigue.ConclusionsWomen with IIMs suffer from autoimmune multimorbidity and experience increased fatigue compared to men.
Pain in individuals with idiopathic inflammatory myopathies, other systemic autoimmune rheumatic diseases, and without rheumatic diseases: A report from the COVAD study
Kim, Minchul , Missé, Rafael Giovani , Naveen, R, Day, Jessica , Cordeiro, Rafael Alves , Júnior, Jucier Gonçalves , Chatterjee, Tulika , Kardeş, Sinan , Milchert, Marcin , Salim, Babur , Velikova, Tsvetelina , Parodis, Ioannis , Selva-O’Callaghan, Albert , Nikiphorou, Elena , Tan, Ai Lyn , Ziadé, Nelly , Kuwana, Masataka , Nune, Arvind , Chinoy, Hector , Agarwal, Vikas , Gupta, Latika, Group, COVAD Study, Singh, Yogesh Preet , Ravichandran, Naveen , Gupta, Latika , Naveen, R , Kardes, Sinan , Gheita, Tamer , Parodis, Ioannis , Selva O'Callaghan, Albert , Saavedra, Miguel A , Ziade, Nelly , Agarwal, Vikas , Gupta, Latika , Milchert, Marcin , Day, Jessica , Velikova, Tsvetelina , Tan, Ai Lyn , Chatterjee, Tulika , Chinoy, Hector , Nune, Arvind , Singh, Yogesh Preet , Shinjo, Samuel Katsuyuki , Hoff, Leonardo Santos , Sen, Parikshit , Lilleker, James B , Agarwal, Vishwesh , Gheita, Tamer A. , Gracia‐Ramos, Abraham Edgar , Makol, Ashima , Cavagna, Lorenzo , Knitza, Johannes , Distler, Oliver , Aggarwal, Rohit , Group, COVAD Study

Mayo Clinic

International Journal of Rheumatic Diseases | March 5, 2023 | Volume: 26 | Issue: 4 | Pages: 727-739

10.1111/1756-185x.14636 | PMID 36872076 Get It

AbstractObjectivesTo compare pain intensity among individuals with idiopathic inflammatory myopathies (IIMs), other systemic autoimmune rheumatic diseases (AIRDs), and without rheumatic disease (wAIDs).MethodsData were collected from the COVID‐19 Vaccination in Autoimmune Diseases (COVAD) study, an international cross‐sectional online survey, from December 2020 to August 2021. Pain experienced in the preceding week was assessed using numeral rating scale (NRS). We performed a negative binomial regression analysis to assess pain in IIMs subtypes and whether demographics, disease activity, general health status, and physical function had an impact on pain scores.ResultsOf 6988 participants included, 15.1% had IIMs, 27.9% had other AIRDs, and 57.0% were wAIDs. The median pain NRS in patients with IIMs, other AIRDs, and wAIDs were 2.0 (interquartile range [IQR] = 1.0–5.0), 3.0 (IQR = 1.0–6.0), and 1.0 (IQR = 0–2.0), respectively (P < 0.001). Regression analysis adjusted for gender, age, and ethnicity revealed that overlap myositis and antisynthetase syndrome had the highest pain (NRS = 4.0, 95% CI = 3.5–4.5, and NRS = 3.6, 95% CI = 3.1–4.1, respectively). An additional association between pain and poor functional status was observed in all groups. Female gender was associated with higher pain scores in almost all scenarios. Increasing age was associated with higher pain NRS scores in some scenarios of disease activity, and Asian and Hispanic ethnicities had reduced pain scores in some functional status scenarios.ConclusionPatients with IIMs reported higher pain levels than wAIDs, but less than patients with other AIRDs. Pain is a disabling manifestation of IIMs and is associated with a poor functional status.
Safety and tolerance of vaccines against SARS-CoV-2 infection in systemic lupus erythematosus: results from the COVAD study
Naveen, R, Nikiphorou, Elena , Joshi, Mrudula , Sen, Parikshit , Lindblom, Julius , Agarwal, Vishwesh , Tan, Ai Lyn , Salim, Babur , Ziadé, Nelly , Velikova, Tsvetelina , Gracia‐Ramos, Abraham Edgar , Kuwana, Masataka , Chinoy, Hector , Tehozol, Erick Adrian Zamora , Torre, Ignacio García-De La, Group, COVAD Study, Singh, Yogesh Preet , Ranjan, Rajiv , Pandya, Sapan C , Sharma, Aman , Manoj, Manesh , Patro, Pradeepta Sekhar , Ajmani, Sajal , Chowdhury, Abhra Chandra , Shenoy, Padnamabha, Bommakanti, Keerthi Talari, Shukla, Anuj , Pandey, Arun Kumar R, Kardeş, Sinan , Kim, Minchul , Pauling, John D , Wincup, Chris , Sambataro, Gianluca , Atzeni, Fabiola , Parisi, Simone , Bocci, Elena Bartoloni, Sainaghi, Pier Paolo , Orsolini, Giovanni , Angelis, Rossella De , Danielli, Maria Giovanna, Milchert, Marcin , Serrano, Jorge Rojas, Torre, Ignacio García-De La, Loarce‐Martos, Jesus , Prieto‐González, Sergio , Kuwana, Masataka, Nakashima, Ran , Sato, Shinji , Kimura, Naoki , Kaneko, Yuko , Tomaras, Stylianos, Aharonov, Or, Maurier, F. , Meyer, Alain , Nagy‐Vincze, Melinda , Limaye, Vidya, Needham, Merrilee , Srivastav, Nilesh , Hudson, Marie, Landon‐Cardinal, Océane , Shaharir, Syahrul Sazliyana , Zuleta, Wilmer Gerardo Rojas, Silva, José António Pereira, Gupta, Latika, Agarwal, Vikas , Parodis, Ioannis , Ravichandran, Naveen , Danieli, Maria Giovanna , Gupta, Latika , Naveen, R , Lilleker, James B , Tan, Ai Lyn , Ziade, Nelly , Gracia-Ramos, Abraham Edgar , Kuwana, Masataka , Day, Jessica , Distler, Oliver , Chinoy, Hector , Gupta, Latika , Parodis, Ioannis , Milchert, Marcin , Agarwal, Vikas , Joshi, Mrudula , Agarwal, Vishwesh , Salim, Babur , Velikova, Tsvetelina , Pauling, John D , Wincup, Chris , Zamora Tehozol, Erick Adrian , Sen, Parikshit , De Angelis, Rossella , Singh, Yogesh Preet , Day, Jessica , Makol, Ashima , Distler, Oliver , Traboco, Lisa S , Wibowo, Suryo Anggoro Kusumo , Rojas Serrano, Jorge , Torre, Ignacio García-De La, Group, COVAD Study, Barman, Bhupen , Jain, Avinash , Pilania, Rakesh Kumar , Gupta, Vikas , Kavadichanda, Chengappa G. , Phatak, Sanat B. , Goswami, Rudra P , Mathew, Ashish Jacob , Asranna, Ajay , Chandwar, Kunal , Cansu, Döndü Üsküdar , Chatterjee, Tulika , Cavagna, Lorenzo , Papa, Nicoletta Del , Govoni, Marcello , Bocci, Elena Bartoloni, Sebastiani, Gian Domenico , Fusaro, Enrico , Sebastiani, Marco , Quartuccio, Luca , Franceschini, Franco , Venerito, Vincenzo , Serrano, Jorge Rojas, Torre, Ignacio García-De La, Gil‐Vila, Albert , Gonzalez, Raquel Aranega, Kuwana, Masataka, Yoshida, Akira, Knitza, Johannes , Tomaras, Stylianos , Gromova, Margarita Aleksandrovna , Gheita, Tamer A. , Hmamouchi, Ihsane , Hoff, Leonardo Santos , Giannini, Margherita , Campagne, Julien , Langguth, Daman , Limaye, Vidya , Silva, José António Pereira, Fonseca, João Eurico , Zimba, Olena , Aggarwal, Rohit

Mayo Clinic

Rheumatology | November 21, 2022 | Volume: 62 | Issue: 7 | Pages: 2453-2463

10.1093/rheumatology/keac661 | PMID 36413073 Get It

Abstract Objective To determine COVID-19 vaccine-related adverse events (AEs) in the seven-day post-vaccination period in patients with SLE vs autoimmune rheumatic diseases (AIRDs), non-rheumatic autoimmune diseases (nrAIDs), and healthy controls (HC). Methods Data were captured through the COVID-19 Vaccination in Autoimmune Diseases (COVAD) questionnaire (March–December 2021). Multivariable regression models accounted for age, gender, ethnicity, vaccine type and background treatment. Results Among 9462 complete respondents, 583 (6.2%) were SLE patients (mean age: 40.1 years; 94.5% females; 40.5% Asian; 42.9% Pfizer-recipients). Minor AEs were reported by 83.0% of SLE patients, major by 2.6%, hospitalization by 0.2%. AE and hospitalization frequencies were similar between patients with active and inactive SLE. Rashes were more frequent in SLE patients vs HC (OR; 95% CI: 1.2; 1.0, 1.5), chills less frequent in SLE vs AIRDs (0.6; 0.4, 0.8) and nrAIDs (0.5; 0.3, 0.8), and fatigue less frequent in SLE vs nrAIDs (0.6; 0.4, 0.9). Pfizer-recipients reported higher overall AE (2.2; 1.1, 4.2) and injection site pain (2.9; 1.6, 5.0) frequencies than recipients of other vaccines, Oxford/AstraZeneca-recipients more body ache, fever, chills (OR: 2.5, 3.0), Moderna-recipients more body ache, fever, chills, rashes (OR: 2.6, 4.3). Hospitalization frequencies were similar across vaccine types. AE frequencies were similar across treatment groups, although chills were less frequent in antimalarial users vs non-users (0.5; 0.3, 0.9). Conclusion While COVID-19 vaccination-related AEs were reported by four-fifths of SLE patients, those were mostly minor and comparable to AEs reported by healthy individuals, providing reassurance regarding COVID-19 vaccination safety in SLE.
Impaired physical function in patients with idiopathic inflammatory myopathies: results from the multicentre COVAD patient-reported e-survey
Yoshida, Akira , Kim, Minchul , Kuwana, Masataka , Ravichandran, Naveen , Makol, Ashima , Sen, Parikshit , Agarwal, Vishwesh , Kardeş, Sinan , Day, Jessica , Milchert, Marcin , Joshi, Mrudula , Salim, Babur , Velikova, Tsvetelina , Gracia‐Ramos, Abraham Edgar , Parodis, Ioannis , Selva-O’Callaghan, Albert , Nikiphorou, Elena , Chatterjee, Tulika , Tan, Ai Lyn , Nune, Arvind , Ziadé, Nelly , Chinoy, Hector , Agarwal, Vikas , Gupta, Latika, Group, COVAD Study, Singh, Yogesh Preet , Jain, Avinash , Pandya, Sapan C , Sharma, Aman , Manesh, Manoj M, Patro, Pradeepta Sekhar , Ajmani, Sajal , Chowdhury, Abhra Chandra , Shenoy, Padnamabha, Asranna, Ajay, Bommakanti, Keerthi Talari, Shukla, Anuj , Pandey, Arun Kumar R, Pauling, John D , Sambataro, Gianluca , Atzeni, Fabiola , Govoni, Marcello, Bocci, Elena Bartoloni, Orsolini, Giovanni , Danielli, Maria Giovanna, Tehozol, Erick Adrian Zamora , Loarce‐Martos, Jesus , Prieto‐González, Sergio , Nakashima, Ran , Sato, Shinji, Kaneko, Yuko , Tomaras, Stylianos , Aharonov, Or, Maurier, F. , Meyer, Alain, Nagy‐Vincze, Melinda , Limaye, Vidya , Needham, Merrilee , Srivastav, Nilesh , Hudson, Marie , Landon‐Cardinal, Océane , Shaharir, Syahrul Sazliyana , Zuleta, Wilmer Gerardo Rojas, Silva, José António Pereira, Gupta, Latika , Lilleker, James B , Day, Jessica , Gracia-Ramos, Abraham Edgar , Parodis, Ioannis , Selva O'Callaghan, Albert , Tan, Ai Lyn , Nune, Arvind , Ziade, Nelly , Knitza, Johannes , Distler, Oliver , Chinoy, Hector , Gupta, Latika , Milchert, Marcin , Agarwal, Vikas , Joshi, Mrudula , Agarwal, Vishwesh , Kim, Minchul , Makol, Ashima , Velikova, Tsvetelina , Chatterjee, Tulika , Pauling, John D , Naveen, R , Zamora Tehozol, Erick Adrian , Sen, Parikshit , Yoshida, Akira , Singh, Yogesh Preet , Gheita, Tamer A. , Cavagna, Lorenzo , Saavedra, Miguel A , Shinjo, Samuel Katsuyuki , Distler, Oliver , Aggarwal, Rohit , Group, COVAD Study, Barman, Bhupen , Ranjan, Rajiv , Pilania, Rakesh Kumar , Gupta, Vikas , Kavadichanda, Chengappa G. , Phatak, Sanat B. , Goswami, Rudra P , Mathew, Ashish Jacob , Chandwar, Kunal , Cansu, Döndü Üsküdar , Wincup, Chris , Papa, Nicoletta Del , Parisi, Simone , Bocci, Elena Bartoloni, Sebastiani, Gian Domenico , Fusaro, Enrico , Sebastiani, Marco , Quartuccio, Luca , Franceschini, Franco , Sainaghi, Pier Paolo , Angelis, Rossella De , Venerito, Vincenzo , Traboco, Lisa S , Wibowo, Suryo Anggoro Kusumo , Rojas Serrano, Jorge , Torre, Ignacio García‐De La , Gil‐Vila, Albert , Gonzalez, Raquel Aranega, Kimura, Naoki, Gromova, Margarita Aleksandrovna , Hmamouchi, Ihsane , Hoff, Leonardo Santos , Giannini, Margherita , Campagne, Julien , Meyer, Alain , Langguth, Daman , Silva, José António Pereira, Fonseca, João Eurico , Zimba, Olena

Mayo Clinic

Rheumatology | August 3, 2022 | Volume: 62 | Issue: 3 | Pages: 1204-1215

10.1093/rheumatology/keac441 | PMID 35920795 Get It

AbstractObjectivesThe assessment of physical function is fundamental in the management of patients with idiopathic inflammatory myopathies (IIMs). We aimed to investigate the physical function of patients with IIMs compared with those with non-IIM autoimmune rheumatic diseases (AIRDs) utilizing Patient-Reported Outcome Measurement Information System (PROMIS) Physical Function (PF) data obtained in the COVAD study, an international self-reported e-survey assessing the safety of COVID-19 vaccines in AIRDs.MethodsDemographics, AIRD diagnosis, disease activity, and PROMIS PF short form-10a data were extracted from the COVAD database. PROMIS PF-10a scores were compared between disease categories and stratified by disease activity. Factors affecting PROMIS PF-10a scores other than disease activity were identified by multivariable regression analysis in patients with inactive disease.ResultsA total of 1057 IIM patients, 3635 non-IIM AIRD patients and 3981 healthy controls (HCs) responded to the COVAD e-survey from April to August 2021. Using a binomial regression model, the predicted mean of PROMIS PF-10a scores was significantly lower in IIM patients compared with non-IIM AIRD patients or HCs [36.3 (95% CI 35.5, 37.1) vs 41.3 (95% CI 40.2, 42.5) vs 46.2 (95% CI 45.8, 46.6), P &lt; 0.001], irrespective of disease activity. The independent factors for lower PROMIS PF-10a scores in patients with inactive disease were older age, female, longer disease duration, and a diagnosis of inclusion body myositis or polymyositis.ConclusionPhysical function is significantly impaired in IIMs compared with non-IIM AIRDs or HCs, even in patients with inactive disease. Our study highlights a critical need for better strategies to minimize functional disability in patients with IIMs.
COVID‐19 Vaccination in Autoimmune Diseases (COVAD) study: Vaccine safety in idiopathic inflammatory myopathies
Gil‐Vila, Albert , Ravichandran, Naveen , Selva-O’Callaghan, Albert , Sen, Parikshit , Nune, Arvind , Gaur, Prithvi Sanjeevkumar , Joshi, Mrudula , Agarwal, Vishwesh , Kardeş, Sinan , Kim, Minchul , Day, Jessica , Milchert, Marcin , Salim, Babur , Velikova, Tsvetelina , Gracia‐Ramos, Abraham Edgar , Parodis, Ioannis , Nikiphorou, Elena , Tan, Ai Lyn , Chatterjee, Tulika , Ziadé, Nelly , Kuwana, Masataka , Chinoy, Hector , Agarwal, Vikas , Gupta, Latika, Group, COVAD Study, Singh, Yogesh Preet , Needham, Merrilee , Loarce‐Martos, Jesus , Ordóñez, Andrea Bran , Gupta, Latika , Lilleker, James B , Joshi, Mrudula , Agarwal, Vishwesh , Kardes, Sinan , Kim, Minchul , Day, Jessica , Makol, Ashima , Milchert, Marcin , Gheita, Tamer , Salim, Babur , Velikova, Tsvetelina , Gracia-Ramos, Abraham Edgar , Parodis, Ioannis , Nikiphorou, Elena , Tan, Ai Lyn , Chatterjee, Tulika , Cavagna, Lorenzo , Saavedra, Miguel A , Shinjo, Samuel Katsuyuki , Ziade, Nelly , Knitza, Johannes , Kuwana, Masataka , Distler, Oliver , Chinoy, Hector , Agarwal, Vikas , Aggarwal, Rohit , Gupta, Latika , Selva O'Callaghan, Albert , Nune, Arvind , Naveen, R , Sen, Parikshit , Singh, Yogesh Preet , Gonzalez, Raquel Arànega, Makol, Ashima , Gheita, Tamer A. , Shinjo, Samuel Katsuyuki , Distler, Oliver , Aggarwal, Rohit , Group, COVAD Study

Mayo Clinic

Muscle & Nerve | July 23, 2022 | Volume: 66 | Issue: 4 | Pages: 426-437

10.1002/mus.27681 | PMID 35869701 Get It

AbstractIntroduction/AimsIn this study we investigated COVID‐19 vaccination–related adverse events (ADEs) 7 days postvaccination in patients with idiopathic inflammatory myopathies (IIMs) and other systemic autoimmune and inflammatory disorders (SAIDs).MethodsSeven‐day vaccine ADEs were collected in an international patient self‐reported e‐survey. Descriptive statistics were obtained and multivariable regression was performed.ResultsTen thousand nine hundred respondents were analyzed (1227 IIM cases, 4640 SAID cases, and 5033 healthy controls [HCs]; median age, 42 [interquartile range, 30‐455] years; 74% female; 45% Caucasian; 69% completely vaccinated). Major ADEs were reported by 76.3% of the IIM patients and 4.6% reported major ADEs. Patients with active IIMs reported more frequent major (odds ratio [OR], 2.7; interquartile range [IQR], 1.04‐7.3) and minor (OR, 1.5; IQR, 1.1‐2.2) ADEs than patients with inactive IIMs. Rashes were more frequent in IIMs (OR, 2.3; IQR, 1.2‐4.2) than HCs. ADEs were not impacted by steroid dose, although hydroxychloroquine and intravenous/subcutaneous immunoglobulins were associated with a higher risk of minor ADEs (OR, 1.9; IQR, 1.1‐3.3; and OR, 2.2; IQR, 1.1‐4.3, respectively). Overall, ADEs were less frequent in inclusion‐body myositis (IBM) and BNT162b2 (Pfizer) vaccine recipients.DiscussionSeven‐day postvaccination ADEs were comparable in patients with IIMs, SAIDs, and HCs, except for a higher risk of rash in IIMs. Patients with dermatomyositis with active disease may be at higher risk, and IBM patients may be at lower risk of specific ADEs. Overall, the benefit of preventing severe COVID‐19 through vaccination likely outweighs the risk of vaccine‐related ADEs. Our results may inform future guidelines regarding COVID‐19 vaccination in patients with SAIDs, specifically in those with IIMs. Studies to evaluate long‐term outcomes and disease flares are needed to shed more light on developing future COVID‐19 vaccination guidelines.
Communicating Value in Simulation: Cost–Benefit Analysis and Return on Investment
Asche, Carl V. , Kim, Minchul , Brown, Alisha, Golden, Antoinette, Laack, Torrey A. , Rosario, Javier , Strother, Christopher , Totten, Vicken Y. , Okuda, Yasuharu

Mayo Clinic

Academic Emergency Medicine | October 1, 2017 | Volume: 25 | Issue: 2 | Pages: 230-237

10.1111/acem.13327 | PMID 28965366 Get It

AbstractValue‐based health care requires a balancing of medical outcomes with economic value. Administrators need to understand both the clinical and the economic effects of potentially expensive simulation programs to rationalize the costs. Given the often‐disparate priorities of clinical educators relative to health care administrators, justifying the value of simulation requires the use of economic analyses few physicians have been trained to conduct. Clinical educators need to be able to present thorough economic analyses demonstrating returns on investment and cost‐effectiveness to effectively communicate with administrators.At the 2017 Academic Emergency Medicine Consensus Conference “Catalyzing System Change through Health Care Simulation: Systems, Competency, and Outcomes,” our breakout session critically evaluated the cost‐benefit and return on investment of simulation. In this paper we provide an overview of some of the economic tools that a clinician may use to present the value of simulation training to financial officers and other administrators in the economic terms they understand. We also define three themes as a call to action for research related to cost–benefit analysis in simulation as well as four specific research questions that will help guide educators and hospital leadership to make decisions on the value of simulation for their system or program.